phenylpropanolamine (PPA)
Jump to navigation
Jump to search
Introduction
FDA has removed phenylpropanolamine from the market 12/2000. Isolated cases of hemorrhagic stroke in young women have been associated with phenylpropanolamine.[4]
Dosage
25 mg PO every 4 hours
Tabs: 25 & 50 mg.
Sustained-release: 75 mg PO every 12 hours. Tabs: 75 mg.
Pharmacokinetics
- metabolized in liver to largely inactive metabolites
- metabolites excreted by the kidney
elimination via liver
Adverse effects
- insomnia
- agitation
- nervousness
- hyperthermia
- hyperventilation
- hypertension
- convulsions
- hemorrhagic stroke in young women (rare) Test interferences:
- may cause false positives in immunoassays for amphetamines in urine
Mechanism of action
More general terms
Component of
- pheniramine/phenylpropanolamine/pyrilamine
- pheniramine/phenylpropanolamine/phenyltoloxamine/pyrilamine
- hydrocodone/pheniramine/phenylephrine/phenylpropanolamine/pyrilamine
- dextromethorphan/guaifenesin/phenylpropanolamine/pyrilamine
- dextromethorphan/guaifenesin/phenylpropanolamine
- clemastine/phenylpropanolamine
- citrate/pheniramine/phenylpropanolamine/phenyltoloxamine/pyrilamine
- chlorpheniramine/phenylpropanolamine/pseudoephedrine
- chlorpheniramine/hyoscyamine/phenylephrine/phenylpropanolamine/scopolamine
- chlorpheniramine/guaifenesin/phenylpropanolamine
- chlorpheniramine/dextromethorphan/phenylephrine/phenylpropanolamine
- brompheniramine/dextromethorphan/phenylpropanolamine
- brompheniramine/codeine/phenylpropanolamine
- phenylpropanolamine/pyrilamine (Triaminic)
- caramiphen/phenylpropanolamine (Tuss-Ornade, Spansule)
- chlorpheniramine/phenylpropanolamine (Contac 12 hour, Ornade, Decongestant DT, Dura-Tap, Spansule)
- brompheniramine/phenylpropanolamine (Dimetapp)
- chlorpheniramine/phenylephrine/phenylpropanolamine/phenyltoloxamine (Naldecon, Naldelate, Par Decon)
- Triaminic
- guaifenesin/phenylpropanolamine (Entex LA, Ami-Tex LA)
- guaifenesin/phenylephrine/phenylpropanolamine (Entex)
- hydrocodone/phenylpropanolamine (Hycomine, Codamine)
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
- ↑ Kaiser Permanente, Northern California Drug Alert, 11, 2000
- ↑ 4.0 4.1 Phenylpropanolamine Information Page http://wwwfda.gov/cder/drug/infopage/ppa/default.htm
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4786
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=26934
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62941
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62942
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62943
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62944
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9065
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10297